{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:47:53Z","timestamp":1745300873546},"reference-count":33,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The coronavirus disease 2019 (COVID-19) pandemic has greatly affected health-care provision across the globe. Management of chronic ailments has become challenging because of the strained health-care resources and social distancing measures that prevent on-site\n clinical visits and treatments. Hereditary angioedema (HAE) is a debilitating, chronic disease characterized by unpredictable swelling attacks in various parts of the body. Controlling HAE symptoms often requires long-term prophylactic medication use and regular medical care; however, limited\n scientific information has been published about HAE medical care during the COVID-19 pandemic.  <jats:bold>Objective:<\/jats:bold> To gather patient and health-care professional (HCP) perspectives on the global impact that COVID-19 has had, and the future impact it will have on HAE medical care\n and to identify differences in perceptions across economic and geographic boundaries.  <jats:bold>Methods:<\/jats:bold> We conducted two independent but similar online global surveys to capture patient and HCP perspectives on the impact that COVID-19 has had, and the future impact it will have\n on HAE medical care.  <jats:bold>Results:<\/jats:bold> Both patients and HCPs globally reported that the pandemic has limited the availability of HAE medical care, and they expect the restrictions to continue far beyond the pandemic. In addition, the results of our study suggested that telehealth\n use has increased across the globe but has been more successfully implemented in high-income countries.  <jats:bold>Conclusion:<\/jats:bold> Patients and HCPs expect that HAE-related care will be negatively impacted by the pandemic for many years. Disparities in medical care and technologic infrastructure\n may exacerbate these challenges in non\u2010high-income countries. Supportive tools and global infrastructure should be established to provide aid to non\u2010high-income countries throughout the pandemic and several years after.<\/jats:p>","DOI":"10.2500\/aap.2022.43.210099","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:03:14Z","timestamp":1641384194000},"page":"e1-e10","source":"Crossref","is-referenced-by-count":15,"title":["Global perceptions of the current and future impacts of COVID-19 on hereditary angioedema management"],"prefix":"10.2500","volume":"43","author":[{"given":"Vesna","family":"Grivcheva-Panovska","sequence":"first","affiliation":[{"name":"From the Public Health Institution University Clinic of Dermatology, School of Medicine, University Saints Cyril and Methodius, Skopje, North Macedonia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Craig","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pediatrics, Penn State University, Hershey Medical Center, Hershey, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Longhurst","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Auckland, Auckland, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mi","family":"Bara","sequence":"additional","affiliation":[{"name":"Hereditary Angioedema Expertise Centre, S\u00e2ngeorgiu de Mure, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Panovska","sequence":"additional","affiliation":[{"name":"School of Economic, Political, and Policy Sciences, the University of Texas at Dallas, Richardson, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","article-title":"WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020"},{"key":"B2","journal-title":"WHO Coronavirus Disease (COVID-19) Dashboard"},{"key":"B3","first-page":"1","article-title":"COVID-19: the impact of social distancing policies, cross-country analysis","author":"Castex","year":"2020","journal-title":"Econ Disaster Clim Chang"},{"key":"B4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.spc.2020.10.016","article-title":"Impact of COVID-19 on the social, economic, environmental and energy domains: lessons learnt from a global pandemic","volume":"26","author":"Mofijur","year":"2021","journal-title":"Sustain Prod Consum"},{"key":"B5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/trstmh\/traa140","article-title":"The benefits and costs of social distancing in high- and low-income countries","volume":"115","author":"Barnett-Howell","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.abc0035","article-title":"The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries","volume":"369","author":"Walker","year":"2020","journal-title":"Science"},{"key":"B7","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.sapharm.2020.04.007","article-title":"Medication management and adherence during the COVID-19 pandemic: perspectives and experiences from low-and middle-income countries","volume":"17","author":"Kretchy","year":"2021","journal-title":"Res Social Adm Pharm"},{"key":"B8","doi-asserted-by":"crossref","first-page":"e24087","DOI":"10.2196\/24087","article-title":"Use of telehealth during the COVID-19 pandemic: scoping review","volume":"22","author":"Doraiswamy","year":"2020","journal-title":"J Med Internet Res"},{"key":"B9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/17441692.2020.1860249","article-title":"COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs","volume":"16","author":"Nhamo","year":"2021","journal-title":"Glob Public Health"},{"key":"B10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13023-020-01619-x","article-title":"The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys","volume":"15","author":"Lampe","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B11","doi-asserted-by":"crossref","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/all.13384","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2017 revision and update","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fmed.2018.00022","article-title":"Hereditary angioedema: the economics of treatment of an orphan disease","volume":"5","author":"Lumry","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B16"},{"key":"B17"},{"key":"B18","article-title":"World Bank country and lending groups"},{"key":"B19","article-title":"Haegarda (C1 esterase inhibitor subcutaneous [human]) [prescribing information, published 9\/2020]"},{"key":"B20","article-title":"Takhzyro (lanadelumab-flyo) injection [prescribing information, revised 2018]"},{"key":"B21","article-title":"Orladeyo (berotralstat) capsules [prescribing information, revised 12\/2020]"},{"key":"B22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(17)30398-7","article-title":"Inequality and the health-care system in the USA","volume":"389","author":"Dickman","year":"2017","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12939-020-01189-1","article-title":"A distributional regression approach to income-related inequality of health in Australia","volume":"19","author":"Kessels","year":"2020","journal-title":"Int J Equity Health"},{"key":"B24","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMsa0707519","article-title":"Socioeconomic inequalities in health in 22 European countries","volume":"358","author":"Mackenbach","year":"2008","journal-title":"N Engl J Med"},{"key":"B25","article-title":"Update on the impact of COVID-19 in the care of patients with Hereditary Angioedema (HAE): results of a patient and HCP survey","author":"Soteres","year":"2021","journal-title":"Presented at Academy of Managed Care Pharmacy"},{"key":"B26","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/all.14796","article-title":"Impact of anxiety, stress and depression related to COVID-19 pandemic on the course of hereditary angioedema with C1-inhibitor deficiency","volume":"76","author":"Karabacak","year":"2021","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.waojou.2020.100454","article-title":"Does hereditary angioedema make COVID-19 worse?","volume":"13","author":"Xu","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B28","doi-asserted-by":"crossref","first-page":"e57555","DOI":"10.7554\/eLife.57555","article-title":"Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome","volume":"9","author":"van de Veerdonk","year":"2020","journal-title":"Elife"},{"key":"B29","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3389\/fimmu.2020.02014","article-title":"Understanding the pathophysiology of COVID-19: could the contact system be the key?","volume":"11","author":"Meini","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3389\/fimmu.2020.02072","article-title":"Treatment of COVID-19 with conestat alfa, a regulator of the complement, contact activation and kallikrein-kinin system","volume":"11","author":"Urwyler","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaip.2020.11.042","article-title":"COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency","volume":"9","author":"Grumach","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"B32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2500\/aap.2021.42.210066","article-title":"Effect of COVID-19 on hereditary angioedema activity and quality of life","volume":"42","author":"Bostan","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.15585\/mmwr.mm6912e2","article-title":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2022\/00000043\/00000001\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T08:23:57Z","timestamp":1654503837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2022.43.210099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"alternative-id":["1088-5412(20220101)43:1L.1;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2022.43.210099","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}